Revolutionizing DNA Replication: Pegasus Biotech Introduces BPE Plasmid Technology for Efficient and Cost-Effective Gene Therapy

Pegasus Biotech, a full-service biotechnology contract research organization, has recently redesigned the way plasmid DNA replicates. This technology, known as BPE plasmid technology, allows scientists to control the production of DNA in a more efficient and cost-effective way than ever before.

The patented origin used in BPE plasmids remains dormant during fermentation but can be activated at high cell densities to significantly increase replication levels. Unlike existing technologies, it does not rely on antibiotic resistance selection markers and contains minimal bacterial sequences. Additionally, cells transfected with BPE plasmids exhibit up to 7 times higher expression compared to traditional plasmid backbones.

Daniel Wilson, COO of Pegasus Biotech, emphasized the transformative potential of this technology in applications where cost of goods sold (COGS) and patient safety are critical factors. The technology meets project requirements of low cost, minimal bacterial sequences, high expression, and no antibiotic resistance selection marker, paving the way for the development of new vaccines and gene-therapy products.

Pegasus Biotech specializes in biopharmaceutical and vaccine development and offers services spanning seed-to-formulation process development and associated analytical development. They ensure that client projects result in commercially viable products that comply with global regulations. For more information about Pegasus’ services, visit their website at www.pegasusbio.com.

For media inquiries, please contact Daniel Wilson at Pegasus Biotech Inc. at 1-855-498-3398 or via email at [email protected]. This information was sourced from Pegasus Biotech Inc., making them leaders in DNA vaccine development and helping clients bring cutting-edge innovation to the human and animal health markets globally.